Associated Papers
Aging, dauer, and stature phenotypes are conferred by structure-directed missense mutations in the endogenous AGE-1/phosphatidylinositol 3-kinase catalytic subunit.
Wu Y et al.
Biorxiv : the Preprint Server for Biology, 2026
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
Tumor-derived RHOA mutants interact with effectors in the GDP-bound state.
Lin Y et al.
Nature Communications, 2024
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis.
Disel U et al.
The Oncologist, 2024
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR.
Sharma AK et al.
The Journal of Biological Chemistry, 2024
Delineating the RAS Conformational Landscape.
Parker MI et al.
Cancer Research, 2022
NMR 1H, 13C, 15N backbone resonance assignments of the T35S and oncogenic T35S/Q61L mutants of human KRAS4b in the active, GppNHp-bound conformation.
Sharma AK et al.
Biomolecular Nmr Assignments, 2022
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors.
Kwan AK et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.
McFall T et al.
Cell Reports, 2021
Mutation-Induced Impacts on the Switch Transformations of the GDP- and GTP-Bound K-Ras: Insights from Multiple Replica Gaussian Accelerated Molecular Dynamics and Free Energy Analysis.
Chen J et al.
Journal of Chemical Information and Modeling, 2021
1H, 15N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH.
Pálfy G et al.
Biomolecular Nmr Assignments, 2020
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.
Hobbs GA et al.
Cancer Discovery, 2020
Drugging an undruggable pocket on KRAS.
Kessler D et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S et al.
Chemical Society Reviews, 2016
Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G et al.
Plos One, 2014
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.
Smith SC et al.
Cancer Research, 2012
A genomic strategy to elucidate modules of oncogenic pathway signaling networks.
Chang JT et al.
Molecular Cell, 2009
Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells.
Pattingre S et al.
The Journal of Biological Chemistry, 2003
A distinct class of dominant negative Ras mutants: cytosolic GTP-bound Ras effector domain mutants that inhibit Ras signaling and transformation and enhance cell adhesion.
Fiordalisi JJ et al.
The Journal of Biological Chemistry, 2002
Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1.
Zang M et al.
The Journal of Biological Chemistry, 2002